Anthos Set for Acquisition by Novartis for $3.1 Billion
Deal News | Feb 11, 2025 | Blackstone
Blackstone Life Sciences and Anthos Therapeutics announced a significant agreement whereby Novartis will acquire Anthos Therapeutics for up to $3.1 billion. Anthos, which specializes in developing transformative therapies for cardiometabolic diseases, holds exclusive rights to abelacimab, a novel anticoagulant that offers substantial potential in treating atrial fibrillation and cancer-associated thrombosis. The acquisition reflects Blackstone’s strategy of developing innovative products with the potential to address unmet medical needs. Financial details include an initial $925 million payout to Anthos' shareholders, with further conditional payments tied to regulatory and commercial milestones. Advisors involved in the transaction include Goldman Sachs & Co. LLC and Morgan Stanley. The deal signifies a pivotal step in drug development and commercialization in the cardiovascular sector, pending regulatory approvals expected in the first half of 2025.
Sectors
- Biopharmaceuticals
- Private Equity
- Healthcare
Geography
- United States – Anthos Therapeutics is based in Cambridge, Massachusetts, USA.
- Switzerland – Novartis, the acquiring company, is headquartered in Switzerland.
Industry
- Biopharmaceuticals – Anthos Therapeutics operates within the biopharmaceutical industry, focusing on developing medical therapies for cardiometabolic diseases.
- Private Equity – Blackstone Life Sciences, a private equity firm, is a significant player in this transaction, having founded Anthos and facilitated investment and development.
- Healthcare – The transaction involves the acquisition of a company developing healthcare treatments, specifically targeting cardiovascular and thrombosis issues.
Financials
- $3.1 Billion – Potential total purchase price for Anthos by Novartis, contingent on reaching specific milestones.
- $925 Million – Upfront payment to be received by Anthos shareholders upon the closing of the transaction.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Anthos Therapeutics, Inc. | Target Company | Company | A biopharmaceutical company developed by Blackstone, focused on cardiovasculature medical therapies. |
| Blackstone Life Sciences | Selling Company | Company | A private equity platform that founded Anthos and holds a major investment stake. |
| Novartis | Bidding Company | Company | A global healthcare company entering into an agreement to acquire Anthos for its novel drug technology. |
| Goldman Sachs & Co. LLC | Financial Advisor | Company | Financial advisor to Anthos in the acquisition transaction. |
| Morgan Stanley & Co. LLC | Financial Advisor | Company | Supporting financial advisory services for Anthos in the acquisition. |
| Goodwin Procter LLP | Legal Advisor | Company | Legal advisor to Anthos during the acquisition process. |